Shire and NanoMedSyn have entered into a preclinical research collaboration to evaluate a potential ERT using NanoMedSyn's proprietary synthetic derivatives named AMFA.
Prothena Corporation plc (PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel therapies in the neuroscience and orphan categories, today announced a global collaboration with Celgene Corporation (CELG) through a subsidiary, to develop new therapies for a broad range of neurodegenerative diseases.
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.